On April 14, 2026, Maven Clinic announced a major expansion of its Fertility & Family Building program for the 2,300+ employers and health plans on its platform, adding three components: earlier in-platform diagnostic testing (hormone panels, genetic screening, fertility labs); condition-specific care pathways for PCOS, endometriosis, and oncofertility (the latter via partnership with Color Health); and an integration with Oura's FDA-listed ovulation prediction insights from the Oura Ring.

Why It Matters

The Oura partnership signals that consumer wearables — once positioned as competitors to medical-grade fertility devices — are now being absorbed as data feeds for the medical and benefits stack. For Oura, the deal opens a B2B revenue channel beyond direct consumer subscriptions; for Maven, it deepens the moat around its enterprise relationships by becoming the layer where wearable data, lab work, and clinician access converge. For competing femtech and fertility companies (Carrot, Progyny, Stork Club), it raises the integration bar significantly.

The Oura integration is the most consequential piece. By pulling continuous body-temperature and heart-rate data from a wearable that millions of users already own — and that received FDA clearance for ovulation prediction last year — Maven is functionally building a continuous fertility-tracking layer into its enterprise care navigation. CEO Kate Ryder framed the strategy in financial terms: "Time lost early becomes dollars spent later, in more aggressive treatment, higher-risk pregnancies, and preventable NICU stays." Maven cites internal employer data showing 30% of members achieve pregnancy without assisted reproductive technology, 88% report improved workplace productivity during treatment, and an average of $9,600 saved per birth across fertility and maternity care.

Maven has raised more than $425M from General Catalyst, Sequoia, and others, and is one of the largest standalone women's health companies operating in the U.S. employer benefits market. The fertility expansion lands amid a broader femtech consolidation cycle: Garmin and Natural Cycles announced their FDA-cleared smartwatch contraception integration on March 31; Aavia published its 250M-data-point cycle dataset; and Chexy raised $30M Series A in early April for AI-driven menstrual prediction. Wearable-plus-clinical-coordination is increasingly the dominant architecture for the category.

Sources

Update — 2026-04-30

Initial entry — story first created.

Update — 2026-05-25

Maven Clinic launched a direct-to-consumer virtual clinic nationwide on May 20, 2026, integrating GLP-1 weight management with comprehensive hormonal care (perimenopause, menopause) and access to 30+ medical specialties. CEO Kate Ryder stated: "Women don't experience their health in silos." Maven's own survey of 1,538 women found 37% reported limited follow-up care after GLP-1 or hormone prescriptions. The platform expansion makes Maven the first women's digital health company to bundle weight management, hormonal care, and reproductive health under a single consumer-facing platform. Maven was also named to TIME's 100 Most Influential Companies of 2026.

New Sources